Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD reviews "public speaking" supplement

This article was originally published in The Tan Sheet

Executive Summary

Deephaven Nutraceuticals discontinues unsupported claims and testimonials for its Bravina dietary supplement in print and Web ads following a National Advertising Division review, according to an Aug. 18 case report. As part of its ongoing monitoring program with the Council for Responsible Nutrition, NAD reviewed claims for the supplement, including claims it is "designed and manufactured for sufferers of public speaking anxiety." The Council of Better Business Bureaus division found the claims were not supported by any studies on the supplement, and that the supplement's nine botanical ingredients, including motherwort and passionflower, have not been found to reduce anxiety specifically related to public speaking. NAD increased scrutiny of dietary supplements in 2007 in part because CRN asked the division to help regulate industry ads (1"The Tan Sheet" Sept. 25, 2006)

You may also be interested in...

CRN Grants $500K To NAD For Increased Dietary Supplement Monitoring

CRN is committing nearly half a million dollars over a three year period to triple the annual number of dietary supplement cases reviewed by the Council of Better Business Bureaus' National Advertising Division (NAD)

Pfizer COVID-19 Vaccine Trial Diversity Slips As Enrollment Rises, Unlike Moderna

Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.

Health And Wellness Trademark Review 8 September, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts